Venus Remedies Ltd announced it has been awarded ₹117.8 million under India’s Production-Linked Incentive (PLI) scheme. The incentive underscores the company’s role in boosting domestic pharmaceutical manufacturing, enhancing competitiveness, and supporting India’s vision of self-reliance in critical healthcare and life sciences sectors.
Venus Remedies Ltd, a leading pharmaceutical company specializing in oncology and critical care drugs, has been awarded ₹117.8 million under the Government of India’s Production-Linked Incentive (PLI) scheme. The announcement, made on January 22, 2026, highlights the company’s contribution to strengthening India’s pharmaceutical manufacturing ecosystem.
Key highlights of the announcement:
-
The ₹117.8M incentive reflects Venus Remedies’ compliance with PLI scheme benchmarks, including capacity expansion and innovation in drug formulations.
-
The PLI scheme aims to boost domestic production of essential medicines, reduce import dependence, and enhance India’s global competitiveness in pharmaceuticals.
-
Venus Remedies has been actively investing in R&D and advanced manufacturing facilities, positioning itself as a key player in oncology and specialty drugs.
-
Analysts note that the incentive will support future growth initiatives, enabling the company to scale production and expand its export footprint.
-
The award also signals the government’s commitment to fostering self-reliance in healthcare, aligning with India’s broader Atmanirbhar Bharat vision.
Industry experts emphasize that Venus Remedies’ recognition under the PLI scheme not only strengthens its financial position but also reinforces its role in driving innovation and accessibility in critical therapies.
Sources: Reuters, Economic Times Pharma Desk, Mint, NSE Corporate Filings